Poolbeg Pharma Raises £4.7m in Oversubscribed Fundraising
Deal News | May 20, 2025 | Shore Capital Markets
Poolbeg Pharma plc successfully raised £4.7 million through an oversubscribed and upsized fundraising effort, with Shore Capital Markets acting as the sole bookrunner and corporate broker. This funding round demonstrates strong investor confidence in Poolbeg Pharma's strategic direction and growth potential. Shore Capital's role was pivotal in orchestrating this successful venture, showcasing their expertise in capital markets. This fundraising effort not only provides Poolbeg Pharma with additional financial resources to support its growth and R&D activities but also underlines the successful partnership between the biotech company and its financial advisor.
Sectors
- Biotechnology
- Financial Services
Geography
- United Kingdom – Poolbeg Pharma and Shore Capital Markets are based in the United Kingdom, which is relevant to the fundraising event.
Industry
- Biotechnology – Poolbeg Pharma operates in the biotechnology sector, focusing on pharmaceutical and drug development.
- Financial Services – Shore Capital Markets, as a financial advisor and broker, is a player within the financial services sector.
Financials
- £4.7 million – Total amount raised by Poolbeg Pharma in the oversubscribed and upsized fundraising.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Poolbeg Pharma plc | Target Company | Company | A pharmaceutical company engaged in biotechnology and drug development. |
| Shore Capital Markets | Sole Bookrunner and Sole Corporate Broker | Company | A financial services company acting as the broker and advisor for the fundraising. |